The complementary roles of genome-wide approaches in identifying genes linked to an inherited risk of colorectal cancer

Abstract

The current understanding of the inherited risk of colorectal cancer (CRC) started with an observational clinical era in the late 19th century, which was followed by a genetic era starting in the late 20th century. Genome-wide linkage analysis allowed mapping several high-risk genes, which marked the beginning of the genetic era. The current high-throughput genomic phase includes genome-wide association study (GWAS) and genome-wide sequencing approaches which have revolutionized the conception of the inherited risk of CRC. On the one hand, GWAS has allowed the identification of multiple low risk loci correlated with CRC. On the other, genome-wide sequencing has led to the discovery of a second batch of high-to-moderate-risk genes that correlate to atypical familial CRC and polyposis syndromes. In contrast to other common cancers, which are usually dominated by a polygenic background, CRC risk is believed to be equally explained by monogenic and polygenic architectures, which jointly contribute to a quarter of familial clustering. Despite the fact that genome-wide approaches have allowed the identification of a continuum of responsible high-to-moderate-to-low-risk variants, much of the predisposition and familial clustering of CRC has not yet been explained. Other genetic, epigenetic and environmental factors might be playing important roles as well. In this review we aim to provide insights on the complementary roles played by different genomic approaches in allowing the current understanding of the genetic architecture of inherited CRC.

Drug development advances in human genetics‐based targets

“…They are involved in several disease areas, such as cardiovascular diseases, oncology, and central nervous system diseases. 304 Among them, WGS for rare diseases is well established.…”

“…In fact, there are many more LOF targets identified through genetic approaches such as GWAS, WES, and WGS that produce favorable clinical effects. They are involved in several disease areas, such as cardiovascular diseases, oncology, and central nervous system diseases 304 . Among them, WGS for rare diseases is well established.…”